Company · Public · BIIB

Biogen Inc.

Neuroscience company developing diranersen (BIIB080 / IONIS-MAPTRx), an antisense oligonucleotide designed to target MAPT mRNA and reduce tau production, evaluated in the Phase 2 CELIA study in early Alzheimer's disease.

Listing

Public

Ticker

BIIB

Headquarters

—

Founded

—

Technology

Antisense oligonucleotide (ASO)

Longevity thesis

If lowering tau production alters the course of an age-associated neurodegenerative disease, MAPT-directed antisense becomes a testable mechanism-level intervention rather than a symptomatic one.

Programmes

DiranersenPhase 2
Alzheimer's disease

Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.